A comparison of pegfilgrastim and filgrastim.
Grigg
Andrew P
AP
Royal Melbourne Hospital, Australia.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D016527:Drug Costs; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006207:Half-Life; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D016867:Immunocompromised Host; D017053:Infection Control; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D010146:Pain / Q000139:chemically induced; D011092:Polyethylene Glycols; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim